Theoretically, the beneficial effect of dobutamine is due to its essential adrenergic action.
Cerebral ischaemic lesions are among the major complications of extreme prematurity. Mean arterial pressure (MAP) below 30 mm Hg precedes such lesions' 2 and requires the use of inotropic drugs to increase or maintain MAP above 30 mm Hg.3 The drugs conventionally used are dopamine and dobutamine, each of which has certain advantages and disadvantages. Dopamine is the drug most often used by neonatalogists,4 although the predominance of its alpha effect during the neonatal period,5 may induce two risk factors: (i) increase in left ventricular afterload and decrease in heart output6 7 and (ii) increased pulmonary resistance associated with a risk of persistent neonatal pulmonary hypertension.8 9 Theoretically, the beneficial effect of dobutamine is due to its essential adrenergic action.
Its inotropic effect has been demonstrated also in preterm neonates,'0 but its ability to increase MAP seems to be more restricted, according to studies in adults" I or young children.'2 As few controlled studies on the haemodynamic effects of these two drugs in the very preterm neonate have been reported, we designed a randomised double blind prospective study to analyse haemodynamic response to each drug within a population of hypotensive preterm infants born at less than 32 weeks' gestation.
Patients and methods

PATIENTS
Institutional approval was obtained for this study. All neonates born before 32 weeks' gestation and admitted to the neonatal intensive care unit of Nantes University Hospital during two periods, from 1 January to 30 September 1990 and from 15 April to 30 September 1992, were eligible. Several conditions had to be met: (i) infants had to present with a MAP below 30 mm Hg for more than one hour despite vascular fill with 20 ml/kg albumin 4%, (ii) infants had to be able to undergo Doppler echocardiographic examination before and during infusion of a positive inotropic drug, and (iii) informed consent had to be obtained from the parents.
DRUG ADMINISTRATION
Neonates included in the study were randomised to either dobutamine or dopamine and received a continuous infusion of dobutamine or dopamine at an initial dose of 5 ug/1kg/min. Whenever MAP could not be maintained above 30 mm Hg, the dose was increased in increments of 5 ,g/kg/min up to a maximum dose of 20 pg/kg/min. When that dose failed, a switch was made to the other drug, with infusion at the same 20 pg/kg/min dose. If MAP could not be maintained above 30 mm Hg after the switch, the subject was withdrawn from the protocol. Drugs were prepared and administered by nurses. Each drug was diluted down to 1000 p,g/ml. The medical team was unaware of randomisation results and prescribed the dosage by adapting the infusion rate.
DATA ANALYSIS AND MEASUREMENTS
The severity of respiratory distress was determined from the arterial alveolar oxygen tension ratio (a/Ao2), PAo2 being computed according 
Results
Twenty preterm infants were enrolled in the study: 10 in the dobutamine group and 10 in the dopamine group (see table 1 The difference between LVO before drug administration and on the maximum dose was + 21 (7)% for the dobutamine group compared with -14 (8)% for the dopamine group (p=0-005). In the dopamine group, we observed a significant positive correlation between a/Ao2 on entry to the trial and the difference between LVO before dopamine administration and at the highest infusion rate of dopamine (r=0-71, n=10, p=0-02; fig 2) . The difference between SVR before drug administration and on the maximum dose was In summary, dopamine would thus seem more suitable than dobutamine as a means of increasing MAP in very preterm neonates. However, dopamine requires special care during hypoxia as there is a significant risk of LVO decrease due to the alpha vasoconstrictor effect. Dobutamine has the advantage of increasing LVO, but has a lesser effect on MAP. Non-invasive LVO monitoring can facilitate the choice of the best inotropic treatment in these hypotensive very preterm neonates.
